A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia

https://doi.org/10.6084/m9.figshare.24250873

media

posted on 2023-10-10, 16:26 authored by Adam S. Kittai, Alan Skarbnik, Miguel Miranda, Alan Yong, Jack Roos, Robert Hettle, Sarah Palazuelos-Munoz, Vikram Shetty, Paolo Ghia

<p dir="ltr">Video abstract for our matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia</p>

Funding

AstraZeneca USA

History

Related Materials

1.
URL - Is published in A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia

Usage metrics

Categories

Oncology and carcinogenesis not elsewhere classified

Keywords

Matching-adjusted indirect comparison (MAIC)chronic lymphocytic leukemia relapsed or refractory chronic lymphocytic leukemia Acalabrutinib Zanubrutinib Indirect treatment comparison (ITC)Indirect treatment comparison matching-adjusted indirect comparison

Licence

Exports